secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001437749-23-022782
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q2 net loss narrows to $2.15M; positive Phase 1 safety data for COVID booster DYAI-100
--------------------------------------------------------------------------------

- Net loss $2.15M (-$0.07/sh) vs -$3.29M (-$0.12/sh) YoY; revenue $837K up from $659K.
- Positive interim Phase 1 data: no major safety issues, immune response at both low and high doses of DYAI-100.
- Cash $10.2M at June 30, 2023, down from $12.7M at Dec 31, 2022.
- New fully funded collaborations: Top 5 pharma for vaccine antigen, EDCL in Bangladesh, Fermbox for alternative proteins.
- Developed animal-free recombinant serum albumin; structurally equivalent to animal-derived product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923022782/0001437749-23-022782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923022782/dyai20230531_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-022782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer